There was no relationship between SLN status and all other clinicopathological variables: stage of the disease, hormonal receptor and HER2/neu status, vascular invasion (assessed by H&E or D2–40), VEGF-A immunostaining, MVD, or LVD (Table 5), after adjusting for tumor size and age. This evidence concerns the gene VEGFA and neoplasm.